Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk: The Legacy of Bisphosphonate Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad context, the dissemination of knowledge regarding bone health and the management of osteoporosis has been a significant focus. Bisphosphonates, a class of drugs widely prescribed to increase bone density, have been a central topic in these discussions. As the scientific community has deepened its exploration of these agents, a specific area of concern has emerged that bridges general health awareness with a more specialized clinical focus. This pivot involves the transition from a broad understanding of medication benefits to a nuanced examination of potential adverse effects associated with long-term exposure. In particular, the relationship between the bisphosphonate Fosamax and the development of osteonecrosis of the jaw represents a critical juncture. This condition, characterized by exposed bone in the maxillofacial region, has prompted a shift in inquiry from general pharmacological safety to the specific risks tied to sustained drug exposure.

Bridging General Knowledge to Specialized Risk: Fosamax and ONJ

The transition now moves from a general health context toward a focused occupational exposure concern, where the duration and intensity of drug exposure become paramount variables in assessing risk. This reframing allows for a more targeted investigation into how prolonged use of such medications may contribute to adverse outcomes in susceptible populations. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ).

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves delayed healing after dental procedures, spontaneous bone exposure, pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, often revealing necrotic bone that fails to heal over several weeks. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Evidence Linking Fosamax to Jaw Necrosis

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Mechanistic pathways linking bisphosphonates to jawbone necrosis are being elucidated through multiscale characterization studies. Research using animal models, such as estrogen-deficient rats treated with alendronate, has examined jawbone-specific responses to bisphosphonate therapy. These studies aim to understand how bisphosphonates affect the jawbone at multiple scales, from tissue mineral density distribution to nanoindentation properties of the bone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone appears to have unique biological and mechanical properties that may predispose it to complications from bisphosphonate-induced suppression of bone turnover. Bisphosphonates accumulate in bone, particularly at sites of high remodeling, and inhibit osteoclast activity. In the jaw, where dental procedures and infections create localized areas of high bone turnover, this suppression can impair healing and lead to necrosis. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Context and Label Warnings for Fosamax-Associated ONJ

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also provides guidance on symptom onset: the time to onset of symptoms varied from one day to several months after starting the drug, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Summary of Evidence

For affected patients, causation-related considerations involve assessing the timeline between exposure and documented harm. The label indicates that ONJ can occur spontaneously or after dental procedures, and the time to onset can range from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk is higher with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ should discontinue Fosamax if severe symptoms develop, and most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label also notes that in placebo-controlled trials, the incidence of these symptoms was similar between groups, suggesting that not all cases are directly attributable to the drug. The presence of known risk factors, such as dental procedures or cancer therapies, complicates the causal assessment. The multiscale characterization of jawbone in animal models provides mechanistic support for a causal link, but human data are limited to observational reports and label warnings. In summary, the scientific evidence establishes a plausible connection between Fosamax and ONJ, supported by pharmacological mechanisms, clinical reports, and animal studies. The prescribing information includes warnings about this risk, with guidance on symptom onset, risk factors, and management. Patients and clinicians should weigh the benefits of Fosamax for osteoporosis and other indications against the potential for ONJ, particularly with long-term use and in the presence of dental risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence includes pharmacological mechanisms, clinical reports, and animal studies. Fosamax inhibits bone resorption, and bisphosphonates accumulate in bone, particularly at sites of high remodeling. In the jaw, this suppression can impair healing and lead to necrosis. Multiscale characterization studies in animal models have examined jawbone-specific responses to bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/). The prescribing information also includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How is osteonecrosis of the jaw diagnosed and what are its symptoms?

ONJ is characterized by exposed, non-healing bone in the maxillofacial region. Symptoms include delayed healing after dental procedures, spontaneous bone exposure, pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, often revealing necrotic bone that fails to heal over several weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.